Alnylam Pharmaceuticals Inc (ALNY)

ALNY · Health Care · United States

Alnylam Pharmaceuticals Inc (ALNY) is a company in the Health Care sector, based in United States. The stock is held in 20 ETFs we track – with its largest weight of 0.52 % in XUHL (msci-usa-health-care). Anyone holding one of these ETFs also owns a small indirect stake in Alnylam Pharmaceuticals Inc.

Above-average ETF coverage: 20 of the 95 ETFs we cover hold Alnylam Pharmaceuticals Inc, spread across 10 indices. That puts the stock in more ETFs than 82.9 % of the 4,334 stocks we cover.

Held in20 ETFs

Highest weight0.52 %

Indices10

SectorHealth Care

CountryUnited States

ISINUS02043Q1076

Data note 1

Price chart

Data note 2

Performance

Performance
Year to date	-39.8 %	1 year	-48.1 %
1 month	+6.6 %	3 months	-15.3 %
Calendar year 2025	+69.0 %

52W

Data note 3

Measured in euros, Alnylam Pharmaceuticals Inc returned -38.7 % year to date and -46.9 % over one year. The gap to the dollar figures above comes from the exchange rate alone: each daily price is converted at the ECB euro reference rate for the same day.

Data note 4

Risk metrics

Max drawdown-58.2 %

Volatility p.a.45.3 %

Data note 5

Below peak-51.3 %

Beta to S&P 5000.38

Correlation to S&P 5000.10

The close on Sep 16, 2026 was 51.3 % below the highest close since Aug 12, 2024, reached on Oct 20, 2025. Over the last 252 trading days, on days when the S&P 500 rose or fell 1 %, Alnylam Pharmaceuticals Inc moved on average 0.38 % in the same direction. The correlation of 0.10 shows how reliable that average is: the broad market explained only a small share of the daily moves.

Data note 6

Correlated with

The strongest co-movers on top, the most inverse below. Low or negative values improve portfolio diversification.

Correlated with
Instrument	r	−1 … +1
Markel Group Inc.	+0.53
Altria Group Inc.	+0.50
Fair Isaac Corporation	+0.44
Essex Property Trust Inc.	+0.43
L3Harris Technologies Inc	+0.43
Norwegian Cruise Line Holdings Ltd.	+0.40
RLC	-0.52
EMCOR Group Inc.	-0.49
Quanta Services Inc.	-0.45

Data note 7

Key financials

Latest reported fiscal year (FY2025, period end 2025-12-31) as filed with the SEC.

Revenue3.7 bn $

Net income0.3 bn $

Diluted EPS2.33 $

Net margin8.4 %

Return on equity39.8 %

Equity ratio15.9 %

Revenue growth+65.2 %

Revenue and profit by fiscal year
Fiscal year	Revenue	Net income	Margin
FY2023	1.8	-0.4	-24.1 %
FY2024	2.2	-0.3	-12.4 %
FY2025	3.7	0.3	8.4 %

Data note 8

Held in these ETFs

Held in these ETFs
ETF	Index	Weight	per €1,000 in the ETF
XUHL / XUHC	msci-usa-health-care	0.52 %	€5.20
XDWH	msci-world-health-care	0.38 %	€3.80
SPFS	msci-world-health-care	0.38 %	€3.80
XDEB	msci-world-minimum-volatility	0.17 %	€1.70
2B7K	msci-world-sri	0.15 %	€1.50
EXXT	nasdaq-100	0.14 %	€1.40
XNAS	nasdaq-100	0.14 %	€1.40
XD9U / XD9D	msci-usa	0.05 %	€0.50
SPYI / SPSA	msci-acwi-imi	0.04 %	€0.40
XDWD / XDWL	msci-world	0.04 %	€0.40
SWWD	msci-world	0.03 %	€0.30
WIMI	msci-world-imi	0.03 %	€0.30
SPYY	msci-acwi	0.03 %	€0.30
EUNL	msci-world	0.03 %	€0.30
IUSQ	msci-acwi	0.03 %	€0.30
SPPW	msci-world	0.03 %	€0.30

Data note 9

The last column turns the weight into euros: this much of €1,000 invested in one of these funds is allocated to Alnylam Pharmaceuticals Inc as of the fund's latest holdings list.

Weight in EUNL since 2019

Sep 30, 2019Sep 16, 2026

In EUNL, a fund tracking the MSCI World, Alnylam Pharmaceuticals Inc had a weight of 0.02 % on Sep 30, 2019 and 0.03 % on Sep 16, 2026. Its share peaked at 0.07 % on Sep 30, 2025. The weight rises and falls with the stock's price relative to the other index members, and it also shifts when the index provider changes the composition.

Data note 10

How much Alnylam Pharmaceuticals Inc overlaps with other holdings in a portfolio is shown by the Portfolio X-Ray and the ETF overlap check.

Stocks with similar ETF exposure

Names that reach a portfolio through largely the same funds as Alnylam Pharmaceuticals Inc — the figure counts the ETFs holding both.

Data note 11

Key figures side by side

Key figures compared with stocks of similar ETF exposure
Stock	1 year	Volatility p.a.	Net margin	Revenue growth
Alnylam Pharmaceuticals Inc	-48.1 %	45.3 %	8.4 %	+65.2 %
Neurocrine Biosciences	+6.1 %	36.8 %	16.7 %	+21.4 %
Amgen	+37.8 %	27.7 %	21.0 %	+10.0 %
Vertex Pharmaceuticals Incorporated	+31.1 %	32.0 %	32.9 %	+8.9 %
Regeneron Pharmaceuticals	+34.7 %	35.8 %	31.4 %	+1.0 %
Gilead Sciences	+33.2 %	26.8 %	28.9 %	+2.4 %
Insmed Incorporated	-15.3 %	54.9 %	-210.5 %	+66.7 %
Medline	–	45.7 %	4069.4 %	+11.5 %
Natera	+97.3 %	47.0 %	-9.0 %	+35.9 %

Return and volatility from our daily closing prices in US dollars; margin and growth from the latest SEC annual filing. Fiscal years do not all end on the same date.